Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)*

AIMS: To assess the efficacy and safety of once-daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin ± sulfonylurea. METHODS: In this 24-week, randomized, double-blind, placebo-controlled, parallel-group, multicentre study, participants...

Descripción completa

Detalles Bibliográficos
Autores principales: Seino, Y, Min, K W, Niemoeller, E, Takami, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466411/
https://www.ncbi.nlm.nih.gov/pubmed/22564709
http://dx.doi.org/10.1111/j.1463-1326.2012.01618.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466411/
https://www.ncbi.nlm.nih.gov/pubmed/22564709
http://dx.doi.org/10.1111/j.1463-1326.2012.01618.x

Ejemplares similares